With alopecia areata in the headlines, Clinical Trials Arena looks at a potential shake-up in its drug options and an ...
The event will discuss data from emerging OX40/OX40L inhibitors, including Inmagene’s IMG-007 - the only clinical-stage non-depleting anti-OX40 mAb. A live question and answer session will follow the ...
Hosted on MSN3h
Alopecia vs hair loss: What is the difference?However, there are some forms of treatment that aim to manage symptoms and promote hair regrowth. 1. Corticosteroid creams: It is commonly used to treat the most common form of alopecia, alopecia ...
Aquestive Therapeutics (AQST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
It’s normal to lose about 50 to 100 hairs a day. But it can be upsetting when you notice more hair loss than this, bald ...
Hudson Therapeutics, Inc. Shaperon, Inc. Accelerate the commercialization and global distribution of programs targeting idiopa ...
Stress is one of the leading factors contributing to hair loss, second only to genetics. It can impact your scalp and hair ...
chief executive of the National Alopecia Areata Foundation (NAAF) in the US, said that Olumiant's approval is "a milestone [that] can spark hope for many patients and encourage new treatment ...
Analysts think that alopecia areata could represent a $1 billion-plus opportunity, as current treatment relies on corticosteroid drugs, which suppress the immune system, but can have serious side ...
Equillium Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback